We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Prognostic Value of Blood Cell Counts Investigated

By LabMedica International staff writers
Posted on 29 Oct 2018
The prognosis and treatment of gastric cancer patients after radical gastrectomy mainly depends on classification of malignant tumors (TNM) stage system. More...
However, the prognosis of gastric cancer patients could be various even with the same tumor stage.

Over the past decades, prognostic value of blood test parameters in gastric cancer patients has been investigated by numerous studies, because a blood test is simple, convenient, reproducible and cost-effective. However, the most common parameters been investigated in the previous reports were neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR).

Medical scientists at the Fourth Military Medical University (Xi’an, China) enrolled a total of 3,243 gastric cancer patients from September 2008 to March 2015. There were 2,538 male and 705 female and the median age was 58 years (range 20–90). The median follow-up time was 24.9 months (range 1–75). All patients were treated with radical D2 gastrectomy, defined as a dissection of all the Group 1 and Group 2 nodes, and regular follow up.

Preoperative blood test was performed within seven days before surgery. Absolute count of white blood cells or leukocytes (WBC), neutrophil, lymphocyte, monocyte and platelet were recorded. Patients with signs of infection were excluded. Clinicopathological data including gender, age, tumor location, tumor size, pathological type, tumor depth, lymph node metastasis and tumor stage were collected. The patients were followed up until November 2015 every three months.

The team reported that the statistically significant optimal cut off value was 6.19 × 109/L for WBC, 4.19 × 109/L for neutrophils, 1.72 × 109/L for lymphocytes, 0.51 × 109/L for monocytes, and 260 × 109/L for platelets, respectively. Neutrophil, lymphocyte, monocyte and platelet were risk factors for the prognosis of gastric cancer. However, only lymphocyte and monocyte were independent risk factors. Combination of lymphocyte and monocyte counts could increase the prognostic value for gastric cancer patients, especially in stage II/III gastric cancer patients.

The authors concluded that absolute count of blood cells was more convenient in predicting the prognosis of gastric cancer patients. High absolute count of neutrophil, monocyte and platelet, and low absolute count of lymphocyte were associated with poor prognosis of gastric cancer. However, only lymphocyte and monocyte count were independent prognostic predictors. The study was published on October 11, 2018, in the journal BMC Gastroenterology.

Related Links:
Fourth Military Medical University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Three presentations will examine Arima Genomics’ high-throughput Hi-C sequencing technology in salivary gland cancer, triple-negative breast cancer, and aggressive cutaneous T-cell lymphoma (Photo courtesy of Arima Genomics)

New Research Examines Hi-C Sequencing Across Solid Tumors and Lymphoma

Arima Genomics (Carlsbad, CA, USA) will present new research highlighting the expanding clinical applications of its Aventa FusionPlus and Aventa Lymphoma tests at the Association for Molecular Pathology... Read more

Immunology

view channel
Image: Study design and collection of lower respiratory tract lining fluid (RTLF) using the PExA instrument. (Aguilera K, Hober A, Greilert Norin N, et al. eBioMedicine, 2026. doi:10.1016/j.ebiom.2026.106538)

Exhaled Breath Particles Reveal Virus-Specific Antibodies in the Lower Airways

Respiratory viruses such as influenza virus, SARS-CoV-2, and respiratory syncytial virus (RSV) require immune protection across the airway mucosa. Antibodies in the respiratory tract lining are important... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: Siemens Healthineers has begun carving out its in vitro diagnostics business as a standalone company named Olyrian Diagnostics (Photo courtesy of Siemens Healthineers)

Siemens Healthineers Begins Transition Toward Standalone Olyrian Diagnostics Business

Siemens Healthineers has begun carving out its in vitro diagnostics business, which will operate as Olyrian Diagnostics. The new name will be introduced in stages as the business prepares to become a standalone... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.